Latest news with #NKH
Yahoo
7 days ago
- General
- Yahoo
West Jordan man allegedly kills roommate's dog, claiming it was a robot
WEST JORDAN, Utah () — A West Jordan man is in custody after he allegedly killed his roommate's dog, claiming it was a robot that had been 'mimicking him,' according to court documents. Drake Montgomery, 23, was booked into the Salt Lake County jail on third-degree felony charges of torturing a companion animal and obstruction of justice, as well as second-degree felony arson. Police say Montgomery was taken into custody on Monday, June 2, shortly after he allegedly attempted to start a fire in Emigration Canyon. After an investigation, officers reported Montgomery had allegedly stabbed his roommate's dog and was in the canyon attempting to dispose of the evidence. Associate Chief Justice John Pearce to step down from Utah Supreme Court The dog was later found in the trunk of Montgomery's vehicle, along with burnt rags, cleaning fluid and a shovel, according to court records. While interviewing with detectives, Montgomery allegedly admitted to punching the dog multiple times and trying to choke the dog. When the dog began to fight back, he reportedly admitted to stabbing it several times. According to court documents, Montgomery believed the dog had been mimicking him and was 'causing him significant stress.' 'He expressed a belief that the dog was not real, but rather a robot, as the dog was neuralinked to him, and he could no longer handle the situation,' the arresting officer wrote in the affidavit. Montgomery was booked on the aforementioned charges and has been ordered to be held without bail, pending a pretrial hearing. Charges are allegations only. All arrested persons are presumed innocent unless and until proven guilty beyond a reasonable doubt. Republicans want to stop judges from issuing nationwide injunctions Self-regulating as a parent Schumer warns of rise in antisemitism White House sends Congress request for $9.4 billion in DOGE cuts Braylynn's battle with Nonketotic Hyperglycinemia (NKH) Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
07-03-2025
- Yahoo
'We're gutted' - Make-A-Wish trip cancelled after Eurostar disruption
A mother has been left "gutted" after a Make-A-Wish trip to Disneyland Paris for her terminally ill daughter Daisy, five, was cancelled due to disruption to Eurostar services following the discovery of an unexploded bomb. Toni Mannion, 38, said she had been "looking forward to making some special memories", but was unable to take alternative transport to France with her daughter who has complex needs. The World War Two explosive, found near Gare du Nord station in Paris, was defused on Friday afternoon - with commuters being told to expect normal services on Saturday. Eurostar's chief safety and stations officer Simon Lejeune said he was "incredibly sorry" for the travel disruption. Paris train services to resume after WW2 bomb defused Five-year old Daisy has a rare metabolic disorder called Nonketotic hyperglycinemia (NKH). She uses a wheelchair, is non-verbal and has severe epilepsy. Ms Mannion travelled from Birmingham to London on Thursday with Dasiy, her one-year-old daughter Lara, her mother and a friend. "We've been planning this for such a long time. Make-A-Wish charity paid for everything from start to finish. "We were really looking forward to making some special memories with the girls. I know Make-A-Wish will look to reorganise. But it's still a bit gutting really. "I cried, we all cried. We've been really looking forward to it. Her [Daisy's] life is limited, we just never know how long we've got left with her. "We wanted to make some really nice memories." Many Britons found themselves stuck on the other side of the Channel on Friday, with no easy way of making it back to UK. But some, like Vicky and her mother Jo, decided to "make the most of it" and spend a few more days in Paris. "We were starting to get a bit worried about being able to get home eventually," said Vicky. Vicky and her mother were only planning on staying one night, but have since decided to book a train back on Sunday. "We're going to make the most of it. We just walked up to the Eiffel tower and are going to have a walk around the city, take our time and enjoy Paris," she said. Many travellers complained about being unable to get on to the Eurostar app, including Bob and Mavis from Nottingham who had been hoping to travel to Paris from London St Pancras International on Friday. "It's taken us hours to get through on the Eurostar app, because it keeps crashing", said Mavis. The couple, who had finally managed to book a train to get them into Paris on Saturday, said they were having to spend money for a hotel in London overnight.
BBC News
07-03-2025
- BBC News
Eurostar: Mother 'gutted' after Make-A-Wish trip cancelled
A mother has been left "gutted" after a Make-A-Wish trip to Disneyland Paris for her terminally ill daughter Daisy, five, was cancelled due to disruption to Eurostar services following the discovery of an unexploded Mannion, 38, said she had been "looking forward to making some special memories", but was unable to take alternative transport to France with her daughter who has complex needs. The World War Two explosive, found near Gare du Nord station in Paris, was defused on Friday afternoon - with commuters being told to expect normal services on Saturday. Eurostar's chief safety and stations officer Simon Lejeune said he was "incredibly sorry" for the travel disruption. Paris train services to resume after WW2 bomb defused Five-year old Daisy has a rare metabolic disorder called Nonketotic hyperglycinemia (NKH). She uses a wheelchair, is non-verbal and has severe Mannion travelled from Birmingham to London on Thursday with Dasiy, her one-year-old daughter Lara, her mother and a friend. "We've been planning this for such a long time. Make-A-Wish charity paid for everything from start to finish. "We were really looking forward to making some special memories with the girls. I know Make-A-Wish will look to reorganise. But it's still a bit gutting really."I cried, we all cried. We've been really looking forward to it. Her [Daisy's] life is limited, we just never know how long we've got left with her."We wanted to make some really nice memories."Many Britons found themselves stuck on the other side of the Channel on Friday, with no easy way of making it back to UK. But some, like Vicky and her mother Jo, decided to "make the most of it" and spend a few more days in Paris. "We were starting to get a bit worried about being able to get home eventually," said Vicky. Vicky and her mother were only planning on staying one night, but have since decided to book a train back on Sunday."We're going to make the most of it. We just walked up to the Eiffel tower and are going to have a walk around the city, take our time and enjoy Paris," she said. Many travellers complained about being unable to get on to the Eurostar app, including Bob and Mavis from Nottingham who had been hoping to travel to Paris from London St Pancras International on Friday."It's taken us hours to get through on the Eurostar app, because it keeps crashing", said Mavis. The couple, who had finally managed to book a train to get them into Paris on Saturday, said they were having to spend money for a hotel in London overnight.
Associated Press
07-03-2025
- Business
- Associated Press
Liberyx Therapeutics Announces the Appointment of Dr. Eddy Zhu as Chief CMC Officer
HONG KONG SAR, HONG KONG, March 7, 2025 / / -- Liberyx Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs to treat rare, pediatric neurometabolic diseases, announces the appointment of Eddy Zhu, Ph.D., as Chief CMC Officer. With extensive experience in commercial manufacturing, pharmaceutical development and regulatory approvals, Dr. Zhu is a highly accomplished scientific professional with a proven track record of success as a leader in technical R&D excellence, resulting in numerous peer-reviewed publications, multiple formulation patents, and regulatory approval. 'We are excited to have Eddy join Liberyx Therapeutics as our new Chief CMC Officer,' said Alex Yang, J.D., LL.M., Chair and Chief Executive Officer at Liberyx, 'Eddy's expertise in commercial manufacturing and pharmaceutical development will be invaluable as we continue to make significant advancements in the clinical development.' Dr. Zhu was most recently the Product Development Lead at Sanofi, where he played a critical role in pharmaceutical and non-pharmaceutical formulation and development across oral solids, liquids and injectables. Dr. Zhu also served as a director for the Parenteral Drug Development Team at WuXi AppTec, focusing on small molecule compound, peptide, peptide-drug-conjugate (PDC), and nucleotide projects. Dr. Zhu has held various senior positions with increasing responsibilities in both MNC and small startup environments. Dr. Zhu holds a Ph.D. in Applied Biological Sciences from Ghent University, a Master's degree in Food Technology from K.U. Leuven and Ghent University through the inter-university program and a Bachelor's degree in Plant Protection from Guangxi University. Dr. Zhu also holds a Project Management Professional (PMP) certification from the Project Management Institute (PMI). 'I am honored to join Liberyx team and lead the development and implementation of CMC strategies,' commented Dr. Zhu. 'I look forward to being a key contributor to accelerate Liberyx's pipeline development and bring safe and effective therapies to patients and families living with neurometabolic disorders.' About Liberyx Therapeutics Liberyx Therapeutics is an innovative clinical stage biopharmaceutical company focused on developing treatments for rare diseases affecting children, primarily neurometabolic disorders such as glycine encephalopathy (also known as nonketotic hyperglycinemia, NKH) and urea cycle disorders. Liberyx founded in 2021 with the support of Mstone Partners is currently focused on developing four pipeline candidates, including two combination approaches. Liberyx Therapeutics' largest shareholder Mstone Partners is an entrepreneurial biotech incubator in the form of a holding company which owns and manages a portfolio of drug development companies. Mstone focuses on pediatric and repurposed drugs, rare and neurodegenerative diseases, and innovative technologies for targeted indications. Since its inception in 2016, Mstone has invested in two US and two HK companies, which are now in advanced clinical-stages with the US FDA. Mstone has also established a number of portfolio companies in a centralized, hub-and-spoke model. Legal Disclaimer:
